☆ 4.8 Article

Non-Invasive Measurement Using Deep Learning Algorithm Based on Multi-Source Features Fusion to Predict PD-L1 Expression and Survival in NSCLC

FRONTIERS IN IMMUNOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Pathology

Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer

Jianghua Wu et al.

Summary: An AI system was developed for automated assessment of PD-L1 expression in non-small cell lung cancer, showing strong consistency with pathologists in tumor proportion score calculation. The system has the potential to improve diagnostic accuracy and efficiency by accurately evaluating the percentage of tumor cells expressing PD-L1.

MODERN PATHOLOGY (2022)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology

Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines

David S. Ettinger et al.

Summary: The NCCN Guidelines for NSCLC cover all aspects of management, with recent updates focusing on targeted therapies, immunotherapies, and their respective biomarkers.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

添加到收藏夹

Review Respiratory System

Artificial intelligence-assisted decision making for prognosis and drug efficacy prediction in lung cancer patients: a narrative review

Jingwei Li et al.

Summary: AI, especially those based on deep learning and radiomics, has the potential to improve the accuracy and efficiency of clinical decision-making for lung cancer patients. However, challenges such as insufficient data and poor interpretability still need to be addressed before AI-based models can be widely implemented in clinical practice.

JOURNAL OF THORACIC DISEASE (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study

Zekun Jiang et al.

Summary: In this study, a radiomic signature was developed using pre-treatment CT images to predict PD-L1 expression in NSCLC, with the logistic regression-based model showing the best predictive performance. The radiomic signature outperformed both the clinical model and the radiomics-nomogram model in predicting PD-L1 expression levels, demonstrating its potential as a noninvasive tool for understanding PD-L1 expression in NSCLC patients.

JOURNAL OF DIGITAL IMAGING (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients

Stefano Bracci et al.

Summary: Radiomics applied to CT can be effective in predicting PD-L1 expression in advanced NSCLC patients, guiding therapeutic decisions.

RADIOLOGIA MEDICA (2021)

添加到收藏夹

Article Oncology

Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images

Wei Mu et al.

Summary: The study suggests that quantitative imaging can serve as an alternative to immunohistochemistry for predicting PD-L1 expression status in NSCLC patients treated with immune checkpoint inhibitors. The developed deeply learned score was able to accurately predict durable clinical benefit, progression-free survival, and overall survival in retrospective and prospective cohorts of patients. The findings support the use of this score as a surrogate for PD-L1 measurement in guiding individual treatment decisions.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features

Qiang Wen et al.

Summary: In patients with advanced-stage lung cancer, radiomics features extracted from pretreatment CT images were found to effectively predict PD-L1 expression level and TMB status. Predictive models combining radiomics features with clinical and morphological factors significantly improved the predictive efficacy and provided valuable guidance for immunotherapy in clinical practice.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images

Panwen Tian et al.

Summary: This study utilized a deep learning model to analyze CT images for assessing PD-L1 expression in NSCLC and predicting immunotherapy response. The results showed that PD-L1ES could predict high PD-L1 expression and was associated with clinical outcomes in patients. Combining PD-L1ES with a clinical model improved the prediction of immunotherapy response.

THERANOSTICS (2021)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result

Mengmeng Jiang et al.

ACADEMIC RADIOLOGY (2020)

添加到收藏夹

Article Oncology

Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas

Jiyoung Yoon et al.

THORACIC CANCER (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography

Kang Zhang et al.

CELL (2020)

添加到收藏夹

Review Oncology

Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy

Wei Chang Colin Tan et al.

CANCER COMMUNICATIONS (2020)

添加到收藏夹

Article Oncology

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials

Hossein Borghaei et al.

CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Roy S. Herbst et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas

Ying Zhu et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Review Medicine, Research & Experimental

The application of artificial intelligence and radiomics in lung cancer

Yaojie Zhou et al.

PRECISION CLINICAL MEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography

Diego Ardila et al.

NATURE MEDICINE (2019)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer

Mario Jreige et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

M. D. Hellmann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Multidisciplinary Sciences

Cancer immunotherapy using checkpoint blockade

Antoni Ribas et al.

SCIENCE (2018)

添加到收藏夹

Review Oncology

Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)

J. M. Kim et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Oncology

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer

Joseph McLaughlin et al.

JAMA ONCOLOGY (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Chih-Hao Chang et al.

CELL (2015)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.